BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1385 related articles for article (PubMed ID: 28280994)

  • 41. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
    Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
    PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
    Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
    Front Immunol; 2020; 11():602868. PubMed ID: 33343574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
    Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
    Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
    Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
    Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
    Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
    Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
    Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
    Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
    Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
    Awata-Shiraiwa M; Yokohama A; Kanai Y; Gotoh N; Kasamatsu T; Handa H; Saitoh T; Murakami H; Hirato J; Ikota H; Tsukamoto N
    Acta Haematol; 2023; 146(5):384-390. PubMed ID: 36917966
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgM Plasma Cell Myeloma.
    Lu H; Durkin L; Zhao X; Nakashima MO
    Am J Clin Pathol; 2022 Jan; 157(1):47-53. PubMed ID: 34508562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
    Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
    Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.
    Zou H; Yang R; Liao ZX; Qin TD; Chen P; Zhang BY; Cao YP; Huang HF
    J Clin Lab Anal; 2019 Mar; 33(3):e22827. PubMed ID: 30485557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
    Drandi D; Ferrante M; Borriero M; Ferrero S
    Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The MYD88
    Kapoor P
    Br J Haematol; 2019 Nov; 187(4):413-415. PubMed ID: 31298748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.